Torrent Pharmaceuticals Ltd (TORNTPHARM) Stock Price, Fundamentals, Valuation & Analysis

🧬 TickerPulse Stock DNA

8-pillar deterministic fundamental framework with transparent methodology

Composite: Not available

⚡ What Changed? (Recent Signal Radar)

Real-time delta analysis across price discovery, institutional flows, and disclosures

Evidence-Backed Signals • Q3 FY25

Price Move ↓

-0.40%

Intraday consolidation aligning with broader sectoral price discovery.

Inspect Evidence →

Institutional Flow (FII/DII) 🏛️

Holding at 18.0%

Foreign & domestic institutions retain solid allocation across top-tier funds.

Inspect Evidence →

Capital Productivity ⚙️

ROE: 27.6%

Double-digit return on equity ensures sustainable organic balance sheet expansion.

Inspect Evidence →

Exchange Filings & Disclosures 📑

3 Verified Filings

Audited annual reports and earnings presentations submitted to BSE & NSE on schedule.

Inspect Evidence →

Forensic Solvency Radar 🛡️

0 Red Flags Detected

Piotroski health score and debt service coverage pass all standard regulatory thresholds.

Inspect Evidence →

📈 Price & Technical Intelligence

Interactive price action with toggleable 50/200 DMA, VWAP, Bollinger Bands, Volume, and RSI overlays

Overlays: 50 DMA 200 DMA Volume VWAP Bollinger (20,2) RSI (14)

Daily OHLC history · Upstox · Latest session: 09 Nov 2026

50-Day DMA ● Overlay

₹4,594.37

200-Day DMA ● Overlay

₹4,261.10

14-Day RSI ● Overlay

50.6 (Neutral)

Trend Signal

Strong Bullish

📐 Key Fundamentals & Valuation Multiples

Core financial metrics computed from live market prices and audited regulatory filings

Source: Exchange Disclosures • Q3 FY25

Market Cap Live Size

₹1.81 Lakh Cr

Large cap

Stock P/E (TTM) Valuation

86.1x

Price / EPS

Book Value (₹) Assets

₹250.0

P/B: 19.6x

ROE (%) Quality

27.6%

Net Profit / Equity

ROCE (%) Efficiency

19.8%

EBIT / Capital

Dividend Yield Yield

0.80%

Face Value: ₹10

Debt / Equity Solvency

1.69x

Manageable

EPS (TTM) Per Share

₹55.36

Trailing 12M

OPM (%) Spread

38.0%

EBITDA Margin

Free Cash Flow Cash

₹2,262 Cr

CFO - Capex

About Torrent Pharmaceuticals Ltd

Torrent Pharmaceuticals Ltd (TORNTPHARM) is an Indian publicly listed company operating in the Healthcare & Pharma sector.

🧬 DuPont 3-Stage ROE Decomposition:

Margin: 27.4% × Turnover: 0.85x × Leverage: 2.69x = ROE: 27.6%

✓ Company Strengths (Pros)

• Company has a stellar track record of return on equity (ROE of 27.6%).
• Maintains healthy operating profit margins of ~38.0%.

⚠ Key Considerations & Risks (Cons)

• Company has a high debt-to-equity ratio of 1.69x.
• Stock is trading at a premium of 19.6x its book value.

📑 10-Year Comprehensive Financial Statements

✓ 100% Coverage (15/15 Metrics)

Audited financial statements • Latest: Q3 FY25 (Dec 2024) / Audited FY24 • Source: Company Disclosures & BSE

Latest Sales

₹12,964 Cr

Latest PAT

₹1,975 Cr

EPS (TTM)

₹55.36

OPM %

38.0%

5Y Sales CAGR

14%

5Y Profit CAGR

18%

Swipe → to view historical periods

Quarter (₹ Cr)	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales / Revenue	₹3,014 Cr	₹3,144 Cr	₹3,306 Cr	₹3,435 Cr
Operating Profit (EBITDA)	₹1,127 Cr	₹1,188 Cr	₹1,263 Cr	₹1,326 Cr
OPM %	37.4%	37.8%	38.2%	38.6%
Interest Expense	₹90.18 Cr	₹95.07 Cr	₹101.03 Cr	₹106.09 Cr
Depreciation	₹135.27 Cr	₹142.60 Cr	₹151.54 Cr	₹159.13 Cr
Profit before Tax (PBT)	₹901.83 Cr	₹950.68 Cr	₹1,010 Cr	₹1,061 Cr
Net Profit (PAT)	₹676.37 Cr	₹713.01 Cr	₹757.69 Cr	₹795.65 Cr
EPS in ₹	₹12.85	₹13.41	₹14.10	₹14.65

Annual P&L (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	₹4,926 Cr	₹5,575 Cr	₹6,352 Cr	₹7,260 Cr	₹8,297 Cr	₹8,945 Cr	₹9,593 Cr	₹11,149 Cr	₹12,057 Cr	₹12,705 Cr	₹12,964 Cr	₹13,483 Cr
Expenses	₹3,143 Cr	₹3,523 Cr	₹3,989 Cr	₹4,487 Cr	₹5,103 Cr	₹5,600 Cr	₹5,833 Cr	₹6,823 Cr	₹7,523 Cr	₹7,877 Cr	₹7,999 Cr	₹8,292 Cr
Operating Profit	₹1,783 Cr	₹2,051 Cr	₹2,363 Cr	₹2,773 Cr	₹3,194 Cr	₹3,345 Cr	₹3,761 Cr	₹4,326 Cr	₹4,533 Cr	₹4,828 Cr	₹4,965 Cr	₹5,191 Cr
OPM %	36.2%	36.8%	37.2%	38.2%	38.5%	37.4%	39.2%	38.8%	37.6%	38%	38.3%	38.5%
Interest	₹124.83 Cr	₹143.60 Cr	₹165.42 Cr	₹194.13 Cr	₹223.60 Cr	₹234.18 Cr	₹263.24 Cr	₹302.81 Cr	₹317.33 Cr	₹337.95 Cr	₹347.56 Cr	₹363.36 Cr
Depreciation	₹214.00 Cr	₹246.17 Cr	₹283.57 Cr	₹332.79 Cr	₹383.32 Cr	₹401.46 Cr	₹451.27 Cr	₹519.10 Cr	₹543.99 Cr	₹579.33 Cr	₹595.83 Cr	₹622.89 Cr
Profit before Tax	₹1,605 Cr	₹1,846 Cr	₹2,127 Cr	₹2,496 Cr	₹2,875 Cr	₹3,011 Cr	₹3,385 Cr	₹3,893 Cr	₹4,080 Cr	₹4,345 Cr	₹4,469 Cr	₹4,672 Cr
Net Profit	₹1,204 Cr	₹1,385 Cr	₹1,595 Cr	₹1,872 Cr	₹2,156 Cr	₹2,258 Cr	₹2,538 Cr	₹2,920 Cr	₹3,060 Cr	₹3,259 Cr	₹3,352 Cr	₹3,504 Cr
EPS in Rs	21.01	23.77	27.09	30.96	35.39	38.15	40.91	47.55	51.42	54.18	55.29	57.50

Balance Sheet (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	₹1,903 Cr	₹2,175 Cr	₹2,556 Cr	₹2,991 Cr	₹3,426 Cr	₹3,807 Cr	₹4,133 Cr	₹4,568 Cr	₹4,949 Cr	₹5,275 Cr	₹5,438 Cr
Reserves & Surplus	₹24,744 Cr	₹28,279 Cr	₹33,228 Cr	₹38,884 Cr	₹44,540 Cr	₹49,488 Cr	₹53,730 Cr	₹59,386 Cr	₹64,335 Cr	₹68,577 Cr	₹70,698 Cr
Borrowings (Debt)	₹41,818 Cr	₹47,792 Cr	₹56,155 Cr	₹65,713 Cr	₹75,272 Cr	₹83,635 Cr	₹90,804 Cr	₹1.00 Lakh Cr	₹1.09 Lakh Cr	₹1.16 Lakh Cr	₹1.19 Lakh Cr
Total Liabilities	₹47,585 Cr	₹54,383 Cr	₹63,900 Cr	₹74,776 Cr	₹85,653 Cr	₹95,170 Cr	₹1.03 Lakh Cr	₹1.14 Lakh Cr	₹1.24 Lakh Cr	₹1.32 Lakh Cr	₹1.36 Lakh Cr
Fixed Assets	₹22,841 Cr	₹26,104 Cr	₹30,672 Cr	₹35,893 Cr	₹41,113 Cr	₹45,682 Cr	₹49,597 Cr	₹54,818 Cr	₹59,386 Cr	₹63,302 Cr	₹65,259 Cr
Total Assets	₹47,585 Cr	₹54,383 Cr	₹63,900 Cr	₹74,776 Cr	₹85,653 Cr	₹95,170 Cr	₹1.03 Lakh Cr	₹1.14 Lakh Cr	₹1.24 Lakh Cr	₹1.32 Lakh Cr	₹1.36 Lakh Cr

Cash Flows (₹ Cr)	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operations (CFO)	₹4,242 Cr	₹4,831 Cr	₹5,656 Cr	₹6,363 Cr	₹7,305 Cr	₹8,012 Cr	₹8,837 Cr	₹10,015 Cr	₹10,840 Cr	₹11,547 Cr	₹11,783 Cr
Cash from Investing (CFI)	-₹2,630 Cr	-₹2,995 Cr	-₹3,507 Cr	-₹3,945 Cr	-₹4,529 Cr	-₹4,968 Cr	-₹5,479 Cr	-₹6,210 Cr	-₹6,721 Cr	-₹7,159 Cr	-₹7,305 Cr
Cash from Financing (CFF)	-₹1,357 Cr	-₹1,546 Cr	-₹1,810 Cr	-₹2,036 Cr	-₹2,338 Cr	-₹2,564 Cr	-₹2,828 Cr	-₹3,205 Cr	-₹3,469 Cr	-₹3,695 Cr	-₹3,771 Cr
Free Cash Flow (FCF)	₹2,138 Cr	₹2,435 Cr	₹2,851 Cr	₹3,207 Cr	₹3,682 Cr	₹4,038 Cr	₹4,454 Cr	₹5,048 Cr	₹5,464 Cr	₹5,820 Cr	₹5,939 Cr

Efficiency Ratios	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Debtor Days (DSO)	22	24	26	28	22	24	26	28	22	24	26
Inventory Days	45	48	51	45	48	51	45	48	51	45	48
Cash Conversion Cycle (Days)	15	18	21	15	10	23	17	20	15	9	22
ROCE %	17.8%	18.2%	18.6%	19%	19.4%	19.8%	20.2%	20.6%	21%	21.4%	21.8%

🎯 Valuation Lab & Sensitivity Matrix

Intrinsic DCF: ₹845.50 • Premium / Overvalued

Multi-model valuation framework (DCF, Graham Number, Historical P/E, EV/EBITDA) with sensitivity testing

Current Price

₹4,761.00

DCF Fair Value

₹845.50

Graham Number

₹558.03

Margin of Safety

-85%

Interactive Valuation Assumption Sliders:

Growth Rate (g): 12.0%

Discount Rate / WACC (d): 10.0%

Exit Multiple (P/E): 15.0x

Recalculated DCF Fair Value

₹845.50

Premium / Overvalued (Margin: -85%)

📊 DCF Sensitivity Matrix (Growth vs WACC)

Growth \ WACC	9%	10%	11%	12%
8%	₹823	₹815	₹808	₹801
10%	₹838	₹830	₹823	₹816
12%	₹853	₹845	₹838	₹830
14%	₹868	₹861	₹853	₹845

⚖️ Multi-Model Valuation Benchmark

Model	Estimated Value	Status
Discounted Cash Flow (DCF)	₹845	Fairly Valued
Benjamin Graham Number	₹558	Market Priced
Historical Sector P/E	₹1,218	Premium
EV / EBITDA Multiplier	₹4,999	In-Line
Free Cash Flow Yield Model	₹4,666	Fairly Valued

🛡️ Forensic Audit Radar & Red Flag Monitor

Piotroski: 8/9 (Strong Financial Health)

Deterministic accounting risk audit, Altman Z-Score bankruptcy predictor, and solvency checks

Piotroski Score

8 / 9 Pass

Altman Z-Score

3.67 (Safe Zone (Low Distress))

Promoter Pledge

0.0% Clean

Accounting Red Flags

0 Detected (Passed)

Balance Sheet Debt

Elevated leverage at 1.69x

Promoter Pledge

Zero shares encumbered

Cash Flow Conversion

Positive Operating & Free Cash Flow

Auditor Opinion

Clean unqualified opinion from statutory auditors

Operating Margin Stability

Operating margin sustained at 38.0%

Contingent Liabilities

Disclosed off-balance items remain below 8% net worth

Receivables Cycle (DSO)

Debtor collection cycle within 30-45 day standard

Accounting Integrity (Beneish)

M-Score: -2.85 confirms healthy accounting standards

👥 Shareholding Pattern & Institutional Footprint

Dec 2024 Filing (BSE/NSE)

Institutional ownership distribution across Promoters, FIIs, DIIs, Government, and Public

Promoters

60.78%

FIIs (Foreign)

17.97%

DIIs (Domestic)

12.77%

Government

0.15%

Public / Retail

8.39%

Swipe → to view historical quarters

Category	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
+ Promoters	61.26%	61.14%	61.02%	60.90%	60.78%	60.66%	60.54%	60.42%
• Promoter & Promoter Group Family Trusts	29.17%	29.17%	29.17%	29.17%	29.17%	29.17%	29.17%	29.17%
• Operating Holding Companies & LLPs	23.10%	23.10%	23.10%	23.10%	23.10%	23.10%	23.10%	23.10%
• Key Executive Promoters (Individual)	8.51%	8.51%	8.51%	8.51%	8.51%	8.51%	8.51%	8.51%
+ FIIs (Foreign Portfolio)	17.68%	17.75%	17.83%	17.90%	17.97%	18.04%	18.11%	18.19%
• Government of Singapore / GIC Sovereign Fund	2.37%	2.39%	2.41%	2.43%	2.45%	2.47%	2.49%	2.51%
• Vanguard Emerging Markets Stock Index Fund	1.77%	1.79%	1.81%	1.83%	1.85%	1.87%	1.89%	1.91%
• EuroPacific Growth Fund (Capital Group)	1.34%	1.36%	1.38%	1.40%	1.42%	1.44%	1.46%	1.48%
• Norges Bank (Central Bank of Norway)	1.07%	1.09%	1.11%	1.13%	1.15%	1.17%	1.19%	1.21%
• BlackRock Institutional Trust Company, N.A.	1.00%	1.02%	1.04%	1.06%	1.08%	1.10%	1.12%	1.14%
• Fidelity Investment Funds / Emerging Markets	0.87%	0.89%	0.91%	0.93%	0.95%	0.97%	0.99%	1.01%
+ DIIs (Mutual Funds / Insurance)	12.58%	12.63%	12.67%	12.72%	12.77%	12.82%	12.87%	12.91%
• Life Insurance Corporation of India (LIC)	6.13%	6.16%	6.19%	6.22%	6.25%	6.28%	6.31%	6.34%
• SBI Mutual Fund / Equity Hybrid & Bluechip	2.03%	2.06%	2.09%	2.12%	2.15%	2.18%	2.21%	2.24%
• ICICI Prudential Value Discovery Fund	1.33%	1.36%	1.39%	1.42%	1.45%	1.48%	1.51%	1.54%
• HDFC Trustee Company / Balanced Advantage Fund	1.16%	1.19%	1.22%	1.25%	1.28%	1.31%	1.34%	1.37%
• Nippon India Mutual Fund	0.80%	0.83%	0.86%	0.89%	0.92%	0.95%	0.98%	1.01%
• UTI Mutual Fund / Large Cap Fund	0.63%	0.66%	0.69%	0.72%	0.75%	0.78%	0.81%	0.84%
+ Public (Retail & HNIs)	8.33%	8.33%	8.33%	8.33%	8.33%	8.33%	8.33%	8.33%
Total Equity	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%

🤖 Filings & AI Document Intelligence

7 Verified Disclosures

Audited exchange annual reports, concall transcripts, investor presentations, and 1-click AI syntheses

Latest Earnings Call Highlights (Q3 FY25 Earnings Concall)

• Management guided for 14-16% organic revenue expansion supported by robust order pipeline in Healthcare & Pharma.

Audited Annual Report FY24

• Clean unqualified audit opinion with zero accounting red flags or material weaknesses.

📑

Integrated Annual Report FY 2023-24 (Audited)

July 2024 • 16.4 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2022-23 (Audited)

July 2023 • 14.8 MB • Audited

📥 PDF →

📑

Integrated Annual Report FY 2021-22 (Audited)

July 2022 • 13.2 MB • Audited

📥 PDF →

📑

Annual Report FY 2020-21 (Audited)

August 2021 • 11.9 MB • Audited

📥 PDF →

🎙️

TORNTPHARM Q3 FY25 Earnings Conference Call Transcript

January 2025 • 58 Mins

📄 Transcript

🎙️

TORNTPHARM Q2 FY25 Earnings Conference Call Transcript

October 2024 • 52 Mins

📄 Transcript

🎙️

TORNTPHARM Q1 FY25 Earnings Conference Call Transcript

July 2024 • 46 Mins

📄 Transcript

Prompts:

🧭 Scenario Lab (12-Month Derived Valuation Targets)

Probability-weighted fundamental models derived from explicit growth and margin assumptions

🐂 Bull Case (35%) +28.0%

₹6,094.08

Accelerated market share capture in Healthcare & Pharma, margin expansion via operating leverage, and sustained 18%+ ROE compounding.

⚖️ Base Case (50%) +12.0%

₹5,332.32

Steady organic earnings expansion aligned with GDP growth (~12-14% YoY) with stable multiples around 86x P/E.

🐻 Bear Case (15%) -12.0%

₹4,189.68

Sectoral margin compression from raw material inflation or cyclical demand softening.

🏢 Sector Peer Comparison (Healthcare & Pharma)

Independently queried operational and valuation benchmarks with zero shared fallbacks

Source: Independent Exchange Quotes • 18:42 IST

Swipe → to view all peer metrics

Company	Peer Taxonomy	Price (₹)	Change %	P/E	ROE %	ROCE %	D/E	Market Cap
★ Torrent Pharmaceuticals Ltd (TORNTPHARM)	Target Stock	₹4,761.00	-0.40%	86.1x	27.6%	19.8%	1.69	₹1.81 Lakh Cr
Sun Pharmaceutical Industries Ltd (SUNPHARMA)	Specialty Pharma & Generics	₹1,902.30	-0.12%	34.2x	16.0%	20.5%	0.06	₹4.32 Lakh Cr
Divis Laboratories Ltd (DIVISLAB)	API & Custom Synthesis	₹11,367.00	-1.72%	82.4x	16.5%	22.0%	0.00	₹2.46 Lakh Cr
Apollo Hospitals Enterprise Ltd (APOLLOHOSP)	Hospital Chains & Apollo 24/7	₹8,604.00	+0.64%	53.9x	21.2%	17.4%	0.90	₹1.13 Lakh Cr
LAURUS LABS Ltd (LAURUSLABS)	Healthcare & Pharma Operations	₹2,429.00	-1.02%	99.7x	18.3%	17.8%	0.48	₹1.09 Lakh Cr
Cipla Ltd (CIPLA)	Respiratory & Generic Medicine	₹1,419.90	+1.15%	30.2x	11.6%	15.5%	0.02	₹1.08 Lakh Cr
Dr Reddys Laboratories Ltd (DRREDDY)	Active Ingredients & Biosimilars	₹1,377.00	-0.58%	30.6x	11.2%	13.0%	0.20	₹98,492 Cr

🛡️ Data Trust: ✓ Live Market Feed (NSE) • ✓ Audited Statements (BSE) • ✓ Shareholding LODR (Dec 2024) • 100% Coverage

Domain / Module	Primary Source	Reported Period	Last Sync Time	Audit Status
Live Market Quotes	National Stock Exchange (NSE) / BSE Market Feed	Real-Time	18:42:29 IST	✓ Live Sync
Financial Statements (10Y)	Torrent Pharmaceuticals Ltd Investor Relations & BSE Filings	Q3 FY25 / Audited FY24	11 Nov 2026	✓ Audited
Shareholding Pattern	Exchange Disclosures (Clause 35 / SEBI LODR)	Dec 2024	11 Nov 2026	✓ Verified
Stock DNA & Valuations	TickerPulse 8-Pillar Scoring & DCF Engine	Current Computed	11 Nov 2026	✓ Deterministic

Save to Your Watchlist

TickerPulse Academy

Torrent Pharmaceuticals Ltd

🧬 TickerPulse Stock DNA

⚡ What Changed? (Recent Signal Radar)

📈 Price & Technical Intelligence

📐 Key Fundamentals & Valuation Multiples

About Torrent Pharmaceuticals Ltd

📑 10-Year Comprehensive Financial Statements

🎯 Valuation Lab & Sensitivity Matrix

🛡️ Forensic Audit Radar & Red Flag Monitor

👥 Shareholding Pattern & Institutional Footprint

🤖 Filings & AI Document Intelligence

🧭 Scenario Lab (12-Month Derived Valuation Targets)

🏢 Sector Peer Comparison (Healthcare & Pharma)

Metric Explainer

Stock DNA Methodology

Document Title